When to recommend allogeneic transplant in multiple myeloma

Abstract

Utilization of allogeneic transplant in the management of multiple myeloma has been actively pursued for nearly 30 years. In this paper, the existing data for use of transplant is reviewed as primary therapy, as salvage and for genetic high-risk disease. The relative merits of using a matched-unrelated donor vs. an HLA-matched donor and what impact the introduction of the novel agents has on the decision to transplant will be covered.

Keywords::

• Allogeneic transplant
• matched donors
• matched-unrelated donors
• multiple myeloma
• reduced-intensity conditioning
• transplant

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal